Integral Health Asset Management’s Cabaletta Bio CABA Stock Holding History

Integral Health Asset Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-850,000	Closed	-$1.18M	–	81
2025 Q1	$1.18M	Buy	850,000 +350,000	+70%	+$746K	0.13%	77
2024 Q4	$1.14M	Buy	500,000 +50,000	+11%	+$176K	0.1%	81
2024 Q3	$2.12M	Buy	450,000 +25,000	+6%	+$145K	0.24%	59
2024 Q2	$3.18M	Hold	425,000	–	–	0.3%	64
2024 Q1	$7.25M	Sell	425,000 -95,000	-18%	-$2.04M	0.67%	58
2023 Q4	$11.8M	Buy	520,000 +190,000	+58%	+$3.19M	1.61%	25
2023 Q3	$5.02M	Buy	+330,000	New	+$4.51M	0.7%	52

Other funds holding CABA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 8.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Integral Health Asset Management's CABA Position: Q2 2025 in Review

Integral Health Asset Management sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 850,000 shares — an estimated $1.18M sold.

Integral Health Asset Management first reported a position in CABA in Q3 2023 and held it in 7 quarters. The position peaked at $11.8M in Q4 2023. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

Integral Health Asset Management reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
Integral Health Asset Management sold 850,000 Cabaletta Bio shares in Q2 2025, an estimated $1.18M.
Integral Health Asset Management first reported a position in Cabaletta Bio in Q3 2023 and held it in 7 quarters.
Integral Health Asset Management's Cabaletta Bio position peaked at $11.8M in Q4 2023.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.